Archives seattle-genetics

by in
Entry Author Date Location
Mersana Adds $4M For Next-Generation “Armed” Cancer Drugs 05/01/12 Boston
Abbott’s Humira, the 3rd-in-Class Drug That Toppled Lipitor as No. 1 04/16/12 National
Seattle Genetics Digs Deeper Into the Proverbial Haystack 03/13/12 National
Reinventing Biotech on April 3: Here’s the Agenda 03/08/12 Seattle
Seattle Genetics Gets New Commercial Boss for Early Days of Adcetris 02/23/12 Seattle
Seattle Genetics Sees Updated Side Effect Warning in Drug Label 01/13/12 Seattle
Xconomy Seattle’s Top 12 Life Sciences Stories of the Year 12/28/11 Seattle
The Year in Seattle Biotech: Lots of Acquisitions, Few New Startups 12/22/11 Seattle
Seattle Genetics, Millennium Look to Broaden Reach of Hodgkin’s Drug 12/09/11 Seattle
Scale Venture Partners Gives Up On Healthcare & Life Sciences Investing 11/08/11 San Francisco
Groupon: The IPO With More Sizzle, and Money, Than the Entire Biotech IPO Class of 2011 11/07/11 National
Seattle Genetics Beats Expectations With $10M Sales in Lymphoma Drug Debut 11/03/11 Seattle
Analyst: Seattle Genetics on Pace to Smash Wall Street Forecast with Lymphoma Drug Rollout 10/20/11 Seattle
Fearless Fantasy Football, Uh, I Mean Biotech, Predictions for the Season Ahead 09/06/11 National
Seattle Genetics’ Market Debut, Pathway Gets Bought, Theraclone’s Latest Trick Against HIV, & More Seattle-Area Life Sciences News 08/25/11 Seattle
Video: Seattle Genetics CEO Makes the Case for a $100K Cancer Drug 08/22/11 Seattle
Seattle Genetics Sets Lymphoma Drug Price at $13,500 Per Dose 08/22/11 Seattle
Seattle Genetics: The Next Litmus Test for High Priced Cancer Drugs 08/22/11 National
Seattle Genetics Wins FDA Approval of First Drug, a New Treatment for Lymphomas 08/19/11 Seattle
SeaGen Passes FDA Panel, Ken Stuart’s Journey to Seattle Biomed, the Latest M&A Obsession, & More Seattle-Area Life Sciences News 07/21/11 Seattle
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent 07/18/11 National
Seattle Genetics Lymphoma Drug Gets Second Green Light from FDA Panel 07/14/11 Seattle
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel 07/14/11 Seattle
SeaGen’s Big Day at the FDA, Hutch Nabs $20M HIV Grant, Allozyne’s Nasdaq Plan, & More Seattle-Area Life Sciences News 07/14/11 Seattle
Insider Trader Pleads Guilty in SeaGen Case 07/12/11 Seattle
Seattle Genetics’ New ‘Empowered Antibody’ Looks Clean in FDA Staff Documents 07/12/11 Seattle
Seattle Genetics’ FDA Panel Preview: What You Need to Know This Week 07/12/11 Seattle
SeaGen Preserves Science Culture, Dendreon Sways Medicare, NanoString’s Financing, & More Seattle-Area Life Sciences News 07/07/11 Seattle
Seattle Genetics, On the Verge of Going Commercial, Seeks to Keep Its Scientific Soul 07/05/11 Seattle
Allozyne’s Backdoor IPO, Sound Pharma Fights iPod Deafness, Mirina Vs. Marina Ends, & More Seattle-Area Life Sciences News 06/23/11 Seattle
Page 3 of 9 « previous page · next page »